Plain-English translation of NCT07688356 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called in patients whose brain tumors have a specific genetic change (called a BRAF mutation). The study includes two groups: people with primary brain tumors that started in the brain, and people with brain tumors that spread from cancer elsewhere in the body. Researchers want to see if this medication can slow or stop tumor growth and improve how patients feel.
Many patients with brain tumors that have a BRAF mutation don't have good treatment options left after standard therapies like surgery or radiation stop working. This medication is designed specifically to target cells with this genetic change, and researchers hope it might work better for brain tumors than current options.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth regularly, as directed by your study doctor. You would have regular study visits to check your health through blood tests, imaging scans of your brain and body, and conversations about how you're feeling and managing any side effects. The study will also ask you to complete surveys about your overall quality of life and any changes in your symptoms or physical abilities. Your participation helps researchers understand whether this medication is safe and effective for brain tumors with this genetic change.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
South Korea